Group 1 - The stock price of Jinfang Pharmaceutical-B (02595) increased by over 11%, reaching 43.78 HKD with a trading volume of 78.47 million HKD [1] - At the recent American Association for Cancer Research (AACR) annual meeting, numerous Chinese new drug research enterprises had their product research abstracts selected, with RAS-targeted therapies and antibody/antibody conjugate drugs being prominent areas of focus [1] - Jinfang Pharmaceutical's pipeline includes three innovative products (GFH276, GFS202A, GFH375) that were featured in the poster session of the AACR meeting, indicating their leading position in the domestic targeted therapy landscape [1] Group 2 - Guotou Securities highlighted that Jinfang Pharmaceutical is a globally positioned innovative drug development company focusing on unmet clinical needs in oncology and immune-related diseases [2] - The company has established an integrated matrix for RAS-targeted therapies and is actively expanding its pipeline to include other global new targeted drugs and novel therapy types [2] - The core product of interest in the pipeline is the KRAS G12D inhibitor GFH375, which has shown positive data in pancreatic cancer and non-small cell lung cancer (NSCLC) [2]

Group 1 - The core viewpoint of the article highlights the significant market activity surrounding Jinfang Pharmaceutical-B (02595), including a stock transfer valued at HKD 437 million, representing 3.42% of the company [1] - On September 19, Jinfang Pharmaceutical-B was listed on the Hong Kong Stock Exchange, with its stock price reaching a peak of HKD 50.20, an increase of 146.20% from the issue price, and closing with a gain of 106.47%, bringing its market capitalization close to HKD 15 billion [1] - Jinfang Pharmaceutical focuses on developing new treatment solutions for oncology, autoimmune, and inflammatory diseases, with a product pipeline that includes eight candidate products, five of which are in clinical development, including two core products GFH925 and GFH375 [1]

Core Viewpoint - The recent IPO of Jinfang Pharmaceutical-B (02595) on the Hong Kong Stock Exchange reflects the ongoing bullish trend in the innovative drug sector, with its stock price surging significantly on the first day of trading [1][9]. Market Performance - The Hong Kong Stock Connect Innovative Drug Index has seen a remarkable increase of over 110% since the beginning of the year, following a historical low of 460.24 points last April [3]. - Despite the strong IPO activity, there has been a recent stagnation in the performance of the Hong Kong healthcare indices, raising concerns among investors [3]. Federal Reserve's Impact - The Federal Reserve's recent interest rate cut of 25 basis points is expected to enhance liquidity in the market, potentially benefiting the Hong Kong innovative drug sector as it attracts foreign investment [4]. - The current price-to-earnings ratios for the Hong Kong innovative drug index and the Hang Seng Healthcare Index are significantly lower than their counterparts in A-shares and U.S. biotech indices, indicating a valuation advantage [4]. Long-term Drivers - The current bullish trend in the innovative drug sector is driven by both policy support and the intrinsic value of companies, focusing on "hardcore innovation, global monetization, and performance validation" [5]. - Recent government policies have aimed to support the development of innovative drugs, including a comprehensive plan for drug development and pricing mechanisms [5]. Financial Performance - By mid-2025, 149 Hong Kong-listed pharmaceutical companies are projected to generate a total revenue of 896.12 billion yuan, with a net profit of 61.99 billion yuan, indicating a significant improvement in the sector's fundamentals [6]. - Among these, 36 innovative drug companies are expected to achieve a revenue growth of 15.8%, outperforming the overall industry [6]. Investment Sentiment - Jinfang Pharmaceutical's IPO has set multiple records in the Hong Kong market, reflecting the high investor interest in the innovative drug sector [8]. - The company raised approximately $268 million through its IPO, attracting significant cornerstone investments, which indicates strong market confidence [8]. Investor Outlook - Investors are optimistic about Jinfang Pharmaceutical due to its differentiated product pipeline and proven commercial success, positioning it as a valuable asset in the ongoing innovative drug bull market [11].

Core Viewpoint - The recent IPO of Jinfang Pharmaceutical-B (02595) on the Hong Kong Stock Exchange reflects the ongoing bullish trend in the innovative drug sector, with its stock price surging significantly on the first day of trading [1][9]. Market Performance - The Hong Kong Stock Connect Innovative Drug Index has seen a remarkable increase of over 110% since the beginning of the year, following a historical low of 460.24 points last April [3]. - Despite the strong IPO activity, there has been a recent stagnation in the performance of the innovative drug sector, with the Hang Seng Healthcare Index experiencing consecutive weekly declines for the first time this year [3]. Federal Reserve's Impact - The Federal Reserve's recent interest rate cut of 25 basis points is expected to enhance liquidity in the market, potentially benefiting the Hong Kong market, particularly the innovative drug sector, as global funds may flow towards emerging markets [4]. Valuation and Growth Potential - The current price-to-earnings ratios for the Hong Kong Stock Connect Innovative Drug Index and the Hang Seng Healthcare Index are 36.19 and 35.96, respectively, significantly lower than the over 50 times valuation seen in A-shares and U.S. biotech indices, indicating a valuation advantage [5]. - The innovative drug sector is expected to see a shift from policy-driven growth to a focus on company fundamentals, with "hardcore innovation, globalization, and performance verification" being key investment themes [5]. Financial Performance - By mid-2025, 149 Hong Kong-listed pharmaceutical companies are projected to generate total revenues of 896.12 billion yuan, with a net profit of 61.99 billion yuan, indicating a 29.7% increase [7]. - Among these, 36 innovative drug companies are expected to achieve revenues of 28.5 billion yuan, reflecting a year-on-year growth of 15.8% [7]. IPO Highlights - Jinfang Pharmaceutical's IPO raised approximately 2.68 billion USD, setting records for the Hong Kong 18A sector, with significant backing from major investment firms [9][10]. - The stock opened at 40.00 HKD in the dark market and surged to a high of 50.20 HKD on its first trading day, closing with a 106.47% increase [10]. Investor Sentiment - Investor confidence in Jinfang Pharmaceutical is attributed to its differentiated product pipeline and proven commercial success, positioning it as a strong candidate for long-term value in the ongoing innovative drug bull market [12].

Summary of Key Points Core Viewpoint The article discusses the recent activities on the Hong Kong Stock Exchange (HKEX) from September 15 to September 21, highlighting the number of companies that submitted applications, those that passed hearings, and new listings. Group 1: Companies Submitting Applications - A total of 11 companies submitted applications to the HKEX during the specified period [1] - Notable companies include: - **Meilian Steel Structure (Shanghai) Co., Ltd.**: Ranked third in China's prefabricated steel structure market with a market share of 3.5% [2] - **Hangzhou New Element Pharmaceutical Co., Ltd.**: Focused on developing therapies for metabolic, inflammatory, and cardiovascular diseases [3] - **Jiangsu Zhongrun Solar Technology Co., Ltd.**: Second in global photovoltaic cell manufacturing with a market share of 14.6% [4] - **Beijing Junzheng Integrated Circuit Co., Ltd.**: A leading provider of chips for various high-tech applications [5] - **Shanghai Aike Baifa Biopharmaceutical Technology Co., Ltd.**: Focused on therapies for respiratory and pediatric diseases [7] - **Nuwa Insight Technology Co., Ltd.**: An AI technology company in the insurance sector [8] - **Huaqin Technology Co., Ltd.**: A leading ODM platform for smart products [9] - **Saimite Information Group Co., Ltd.**: A leading provider of intelligent industrial software solutions [10] - **Guangzhou Ruoyu Chen Technology Co., Ltd.**: An e-commerce operation company [11] - **Quantitative Holdings Limited**: Focused on online market operations in the consumer sector [12] - **Hangzhou Xianweida Biotechnology Co., Ltd.**: A biopharmaceutical company nearing commercialization [13] Group 2: Companies Passing Hearings - Two companies successfully passed the listing hearings: - **Shenzhen Xipuni Precision Technology Co., Ltd.**: A designer and manufacturer of gold watch cases and bands [14] - **Xuanzhu Biotechnology Co., Ltd.**: An innovative biopharmaceutical company with multiple drug assets in development [15] Group 3: Companies Launching IPOs - Four companies initiated their IPOs: - **Jingfang Pharmaceutical-B**: Global offering of 89.24 million shares with a net fundraising of approximately HKD 1.67 billion [17] - **Different Group**: Global offering of 10.98 million shares with a price range of HKD 62.01-71.20 [18] - **Chery Automobile**: Global offering of 297 million shares with a price range of HKD 27.75-30.75 [19] - **Zijin Gold International**: Global offering of 349 million shares with a price of HKD 71.59 [20] Group 4: New Listings - Three new stocks were listed: - **Hesai Technology (HK:02525)**: Closed at HKD 234.0 per share, up 9.96% on the first day [20] - **Health 160 (HK:02656)**: Closed at HKD 28.22 per share, up 137.34% on the first day [21] - **Jingfang Pharmaceutical-B (HK:02595)**: Closed at HKD 42.10 per share, up 106.47% on the first day [22]

Group 1 - The core viewpoint of the article highlights the successful debut of Jinfang Pharmaceutical on the Hong Kong Stock Exchange, with a significant stock price increase of 106.5% on its first trading day, closing at HKD 42.1 per share and achieving a total market capitalization of HKD 15.03 billion [1] - Jinfang Pharmaceutical, established in 2017, focuses on the development of innovative therapies for oncology, autoimmune, and inflammatory diseases, with a pipeline that includes 8 candidate products, 5 of which are in clinical development [1] - Financial data indicates that the company's revenues for the years 2023-2024 and the first four months of 2025 were HKD 73.734 million, HKD 105 million, and HKD 82.149 million respectively, while the losses for the same periods were HKD 508 million, HKD 678 million, and HKD 66.624 million [1]

（股份代號：2595） 董事會決議日期 及 中期報告刊發日期 勁方醫藥科技（上海）股份有限公司（「本公司」）董事會（「董事會」）謹此公告，將 於2025年9月30日（星期二）（香港時間）以書面決議方式審議及批准本公司截至 2025年6月30日止六個月的中期報告及其刊發事宜，並審議中期股息派付事宜（如 有）。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容引致的任何損失承擔任何責任。 GenFleet Therapeutics (Shanghai) Inc. 勁方醫藥科技（上海）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 香港，2025年9月19日 於本公告日期，本公司董事會包括：(i)執行董事呂強博士、蘭炯博士及張巍女 士；(ii)非執行董事朱競陽先生及陶莎女士；及(iii)獨立非執行董事盧韶華女士、 周德敏博士及李波先生。 承董事會命 勁方醫藥科技（上海）股份有限公司 董事長兼執行董事 呂強博士 ...

Core Viewpoint - Jinfang Pharmaceutical Technology (Shanghai) Co., Ltd. has successfully listed on the Hong Kong Stock Exchange, with a closing price of HKD 42.10, reflecting a significant increase of 106.47% from its opening price of HKD 44.00 [1] Group 1: Company Overview - Jinfang Pharmaceutical is a biopharmaceutical company focused on developing new treatment solutions for tumors, autoimmune diseases, and inflammatory diseases [1] - The company issued a total of 89,240,000 H shares, with 7,760,000 shares allocated for the Hong Kong public offering and 81,480,000 shares for international offering [2][3] Group 2: Financial Details - The offering price was set at HKD 20.39 per share, raising a total of HKD 1,819.60 million, with a net amount of HKD 1,669.92 million after deducting estimated listing expenses of HKD 149.69 million [2][3] - The net proceeds will be used for clinical development of core products GFH925 and GFH375, further development of other pipeline candidates, and general corporate purposes [3] Group 3: Key Investors - Key cornerstone investors include RTW Master Fund, TruMed Health Innovation Fund LP, OrbiMed Genesis Master Fund, and several asset management firms such as UBS Asset Management and 富国基金管理有限公司 [5][6][7] Group 4: Financial Performance - For the fiscal years ending December 31, 2023, and December 31, 2024, Jinfang Pharmaceutical reported revenues of RMB 73.7 million and RMB 104.7 million, respectively, with a loss of RMB 508.3 million and RMB 677.6 million for the same periods [8][9] - The company has incurred significant operating losses primarily due to research and development costs associated with clinical trials, which have exceeded the revenue generated [9][10]

Market Overview - The Hong Kong stock market showed mixed performance today, with the Hang Seng Index closing flat at 26,545.1 points and a total turnover of HKD 3,768.12 million. The Hang Seng China Enterprises Index rose by 0.17% to 9,472.35 points, while the Hang Seng Tech Index increased by 0.37% to 6,294.42 points. For the week, the Hang Seng Index gained 0.59%, the China Enterprises Index rose by 1.15%, and the Tech Index saw a 5.09% increase [1]. Blue Chip Performance - Sands China (01928) led the blue-chip stocks, rising by 6.19% to HKD 21.6, contributing 4.77 points to the Hang Seng Index. The upcoming National Day and Mid-Autumn Festival holidays have driven demand for gaming stocks, with strong expectations for the Golden Week based on nearly full hotel bookings [2][4]. - Other notable blue-chip performers included China Hongqiao (01378) up 4.67% to HKD 26.46, Galaxy Entertainment (00027) up 4.22% to HKD 42.46, while Hansoh Pharmaceutical (03692) fell by 2.62% to HKD 35, dragging the index down by 1.74 points [2]. Sector Highlights Gaming Sector - The gaming sector saw significant gains, with Melco International Development (00200) up 6.6%, Sands China (01928) up 6.19%, and Wynn Macau (01128) up 6.02%. Macau's gross gaming revenue (GGR) for August reached MOP 22.16 billion, marking a new monthly high, with a year-on-year increase of 12.2% [3][4]. Gold Sector - Gold stocks rebounded, with Shandong Gold (01787) rising by 6.13% to HKD 35.68, Lingbao Gold (03330) up 3.98% to HKD 16.46, and Zijin Mining (02899) up 2.76% to HKD 29.08. The price of spot gold has stabilized above USD 3,650 following the Federal Reserve's interest rate cuts [4]. Coal Sector - Coal stocks performed well, with Yanzhou Coal Mining (01171) up 6.51% to HKD 10.63, and China Shenhua Energy (01088) up 1.42% to HKD 38.46. Recent investigations into overproduction in Inner Mongolia are expected to curb excess supply [5][6]. Robotics Sector - The robotics sector showed mixed results, with Sanhua Intelligent Control (02050) down 6.21% while DCH Holdings (00179) rose by 5.78%. Recent rumors regarding Tesla's robot orders were denied by Elon Musk, but the Chinese government is pushing for the application of humanoid robots in various industries [7]. Notable Stock Movements - Jinfang Pharmaceutical-B (02595) debuted with a remarkable increase of 106.47% to HKD 42.1. The company focuses on developing new treatment solutions for tumors and autoimmune diseases [8]. - Hongteng Precision (06088) surged by 21.44% to HKD 5.89, benefiting from Nvidia's investment in Intel for AI infrastructure [9]. - Cloudfin Financial (00376) rose by 10.55% to HKD 6.39 after appointing a former Ant Group executive to lead its Web3 development [10]. - Weimob Group (02013) increased by 10% to HKD 2.86 following a significant share placement [11]. - Ganfeng Lithium (01772) saw a rise of 9.51% to HKD 37.3, with the company announcing full production capacity for its energy storage cells [12]. - Changfei Optical Fiber (06869) reached a new high, increasing by 8.55% to HKD 61.6, driven by interest in hollow core fiber technology [13][14].

Market Overview - The Hong Kong stock market showed mixed performance with the Hang Seng Index closing flat at 26,545.1 points and a total turnover of HKD 37.68 billion. The Hang Seng China Enterprises Index rose by 0.17% to 9,472.35 points, while the Hang Seng Tech Index increased by 0.37% to 6,294.42 points. For the week, the Hang Seng Index gained 0.59%, the China Enterprises Index rose by 1.15%, and the Tech Index increased by 5.09% [1] Blue Chip Performance - Sands China (01928) led blue-chip stocks with a rise of 6.19% to HKD 21.6, contributing 4.77 points to the Hang Seng Index. The upcoming National Day and Mid-Autumn Festival boosted demand for gaming stocks, with strong expectations for the Golden Week based on nearly full hotel bookings [2][4] - Other notable blue-chip performances included China Hongqiao (01378) up 4.67% to HKD 26.46, and Galaxy Entertainment (00027) up 4.22% to HKD 42.46 [2] Sector Highlights Gaming Sector - The gaming sector saw significant gains, with Melco International Development (00200) up 6.6% and Wynn Macau (01128) up 6.02%. Macau's gaming revenue reached MOP 22.16 billion in August, marking a 12.2% year-on-year increase [3][4] Gold Stocks - Gold stocks rebounded, with Shandong Gold (01787) rising 6.13% to HKD 35.68. The price of spot gold rose above USD 3,650 following the Federal Reserve's interest rate cut, with long-term gold investment still seen as valuable due to ongoing economic concerns [4] Coal Sector - The coal sector performed well, with Yanzhou Coal Mining (01171) up 6.51% to HKD 10.63. Recent investigations into overproduction in Inner Mongolia are expected to stabilize coal production levels [5][6] Robotics Sector - The robotics sector showed mixed results, with Sanhua Intelligent Control (02050) down 6.21% while Delta Electronics (00179) rose 5.78%. Recent news regarding Tesla's plans for humanoid robots has created volatility in this sector [6] Notable Stock Movements - Jinfang Pharmaceutical-B (02595) debuted with a remarkable increase of 106.47% to HKD 42.1, focusing on cancer and autoimmune disease treatments [7] - Hongteng Precision (06088) surged 21.44% to HKD 5.89, benefiting from Nvidia's investment in Intel for AI infrastructure [8] - Cloud Financial (00376) rose 10.55% to HKD 6.39 after appointing a former Ant Group executive to lead its Web3 development [9] - Weimob Group (02013) increased by 10% to HKD 2.86, announcing a share placement to raise approximately HKD 1.555 billion [10] - Ganfeng Lithium (01772) saw a rise of 9.51% to HKD 37.3, with full production capacity in energy storage cells and ongoing developments in solid-state batteries [11] - Yangtze Optical Fibre and Cable (06869) reached a new high, increasing by 8.55% to HKD 61.6, driven by interest in hollow-core fiber optics [12]